Patients with acromegaly, aged >18 y, treated with iSRLs as monotherapy for >6 mo (stable dose >3 mo), with biochemical control (IGF-1 <1.0 x LN based on the average of 2 assessments at SV1 and SV2. The gene discussed is IGF1; the disease is acromegaly.